Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

818651

	registered interest
	date	08/01/2018
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Innovative Medicines and Medical Technology Review
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Government response to the Accelerated Access Review published in November 2017, what plans his Department has to streamline existing routes to market for medical technologies, devices and diagnostics.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	121415
	answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>We are introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. A new Accelerated Access Collaborative (AAC) chaired by Sir Andrew Witty, will develop and own the Accelerated Access Pathway which will be operational from April 2018. All products including medical technologies, devices and diagnostics will be eligible for selection. In addition to the new Pathway, the AAC will also make recommendations to the Government and its partners about opportunities to further streamline existing routes to market.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 12:04:46 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

810500

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Trials: Rare Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department taking to ensure access to European clinical trails for the treatment of rare diseases by UK patients after the UK has left the EU.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	120846
	answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120842 120845 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

810496

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that patient access to medicines currently available in the UK is maintained after the UK leaves the EU.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	120842
	answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120845 120846 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

810495

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that it has adequate medical importation and exportation customs expertise after the UK leaves the EU.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	120841
	answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>Maintaining continuity of medicine supply is a key part of ensuring everyone has continued access to the medicines they need on day one of the United Kingdom’s exit from the European Union and thereafter. The UK is fully committed to continuing the close working relationship with our European partners in the interests of public health and safety; and will seek to ensure that cross-border trade with the EU is as frictionless as possible for the benefit of patients in both the EU and the UK. This will be part of the broader negotiations of the UK’s future relations with the EU and the Department will continue to work closely with Her Majesty’s Revenue and Customs during and after the negotiation period.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2018 15:13:40 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

810499

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of effect of the UK leaving the EU on patients involved in EU clinical trails.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	120845
	answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the UK and the EU. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and the National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 120842 120846 question first answered 11/01/2018 15:35:19 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

820691

	registered interest
	date	11/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to maintain the quality of service of specialist diagnostic workforces in cancer treatment after the UK leaves the EU.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	122109
	answer	answer is ministerial correction date of answer 17/01/2018 answer text <p>We value the enormous contribution of all the staff working in health and social care from across the European Union and the rest of the world. We are committed to ensuring that the National Health Service and social care have the nurses, midwives, doctors, carers and other health professionals that they need to deliver the high quality service on which patients rely following the United Kingdom’s exit from the EU.</p><p> </p><p>The Prime Minister has been very clear that EU citizens living lawfully in the UK will be allowed to stay.</p><p> </p><p>The Department has submitted evidence to the Migration Advisory Committee to ensure the position of staff in health and social care is fully understood and taken into account as part of their evidence gathering into the impact of the UK’s exit from the EU on the UK labour market.</p><p> </p><p>Health Education England published the cancer workforce plan in December 2017 which sets out actions as recommended in the Cancer Strategy for England, including for the diagnostic workforce up to 2020/21. The plan also considers future challenges beyond 2020/21.</p><p> </p><p>It is the responsibility of the devolved governments in Northern Ireland, Scotland and Wales to ensure they have the specialist workforce to deliver cancer services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/01/2018 17:13:09 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

819796

	registered interest
	date	10/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of technology appraisals on medical technologies, devices and diagnostics that the National Institute for Health and Care Excellence undertakes over the next five years.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	121868
	answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>From April 2018 we are introducing a new Accelerated Access Pathway (AAP), to streamline regulatory and market access decisions, getting breakthrough and transformative products to patients more quickly. All products including medical technologies, devices and diagnostics will be eligible for selection. The AAP will complement existing activity and involve a significant role for the National Institute for Health and Care Excellence (NICE), building on existing momentum such as NICE's Fast Track Appraisal Process.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 11:33:14 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

819797

	registered interest
	date	10/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure a funding requirement is placed on medical technologies, devices and diagnostics that receive a positive technology appraisal from the National Institute for Health and Care Excellence.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	121869
	answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>A funding requirement automatically applies to any intervention, including medical technologies, devices and diagnostics, recommended in technology appraisal guidance issued by the National Institute for Health and Care Excellence, in line with the NHS Constitution.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/01/2018 11:29:37 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron

833017

	registered interest
	date	29/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Energy Drinks: Sales
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the merits of setting age restrictions on the sale of high caffeine energy drinks to children to protect their health.
	tabling member constituency	East Kilbride, Strathaven and Lesmahagow
	tabling member printed	Dr Lisa Cameron
	uin	125333
	answer	answer is ministerial correction date of answer 01/02/2018 answer text <p>I refer the hon. Member to the answer I gave the hon. Member for West Lancashire on 15 January 2018 to Questions <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=121787" target="_blank">121787 </a>and <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=121788" target="_blank">121788</a>.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/02/2018 11:37:02 answering member 4067 label Biography information for Steve Brine
	tabling member	4412 label Biography information for Dr Lisa Cameron